Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Jane

Financiado

Cerrado

Harmless Respiration for Intensive Care Patients decreasing mortality and shorte...

Harmless Respiration for Intensive Care Patients decreasing mortality and shortening stays including COVID 19 patients The current outbreak of COVID-19 is incisively pointing towards the importance of optimal mechanical ventilation in Intensive Care. Improved mechanical ventilation saves lives. Last year, we have seen multiple cases in which our m... ver más

31/10/2022

VENTINOVA

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

VENTINOVA MEDICAL BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-10-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 69% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

VENTINOVA

2.50M€ | Lider

SISTEMAS MECANICOS PARA ELEC...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VENTILADOR PULMONAR AVANZADO PARA CUIDADOS IN... VENTILADOR PULMONAR AVANZADO PARA CUIDADOS INTENSIVOS 561K€ Cerrado

AIRMED Mass Casualty Ventilation Monitoring 2M€ Cerrado

DiaMon Continuous Diaphragm Monitoring for mechanically ventilated... 71K€ Cerrado

PDC2023-145905-I00 Ingeniería biomédica 289K€ Cerrado

CPP2021-008930 DESARROLLO DE UN EQUIPO DE MONITORIZACIÓN Y VENTILACIÓN MECÁ... 195K€ Cerrado

COVID-19 ICU-CARE COVID 19 ICU CARE A ground breaking ICU bed side COVID 19... 2M€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2020-07-28
Fecha Fin: 2022-10-31

Líder del proyecto

VENTINOVA MEDICAL BV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The current outbreak of COVID-19 is incisively pointing towards the importance of optimal mechanical ventilation in Intensive Care. Improved mechanical ventilation saves lives. Last year, we have seen multiple cases in which our mechanical ventilator suited only for the Operating Room (OR), was used off-label in ICU to ventilate severely lung-ill patients. Doctors claim patients would have died if our device would not have been used. These case reports are supported by more fundamental evidence published in March 2020: in-vivo studies on pigs having similar lung-illness as with the current COVID-19 outbreak (called Acute Respiratory Distress Syndrome) have shown superior result with our disruptive ventilation method, called FCV®. Half of all patients on higher grade Intensive Care Units need mechanical ventilation. However, current ventilation methods are known to damage the lungs in these vulnerable patients. This significantly prolongs ICU stay and increases mortality. The damages relate to the passive expiratory phase during mechanical respiration, which is fast and uncontrolled resulting in shear stress and collapse of the distal lung parts. Prolonged ventilation then initiates inflammatory responses in the lungs. We have developed a new ventilation method controlling the expiration, preventing lung damage. In 2017 our innovative OR ventilator (Evone) was brought to the market. Having performed over 1,000 OR patient cases and 5 small clinical studies till date, clear superior ventilation and improved lung mechanics has been shown. However, the largest unmet medical need related to ventilation is on ICU. The objective of this proposal is to bring this superior ventilation technology to ICUs in Europe, the Middle East and in 2nd phase the USA and by that, lower ICU mortality by 20% and ICU stay with 15%. This means 44,800 lives to be saved in European ICUs, each year (valued at € 90 billion) and a reduction of €2 billion in annual European healthcare costs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores